WO2011151716A1 - Procédé de purification d'il-11 humaine recombinante - Google Patents

Procédé de purification d'il-11 humaine recombinante Download PDF

Info

Publication number
WO2011151716A1
WO2011151716A1 PCT/IB2011/001220 IB2011001220W WO2011151716A1 WO 2011151716 A1 WO2011151716 A1 WO 2011151716A1 IB 2011001220 W IB2011001220 W IB 2011001220W WO 2011151716 A1 WO2011151716 A1 WO 2011151716A1
Authority
WO
WIPO (PCT)
Prior art keywords
tag
purification
protein
fusion
chromatography
Prior art date
Application number
PCT/IB2011/001220
Other languages
English (en)
Inventor
Praveen Muneshwar
Sriram Padmanabhan
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of WO2011151716A1 publication Critical patent/WO2011151716A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Definitions

  • the invention relates to process for purification of recombinant human IL-1 1 from a soluble IL-1 1 fusion protein expressed in bacterial system.
  • the method involves purification of the soluble fusion protein, digestion to separate the IL- 1 1 from the fusion tag followed by hydrophobic interaction chromatography and ion exchange chromatography.
  • Protein purification varies from simple one step precipitation procedures to large scale validated production processes.
  • the key to successful and efficient protein purification is to select the most appropriate techniques, optimize their performance to suit the requirements and combine them in a logical way to maximize yield and minimize the number of steps required.
  • Most commonly used purification methods include use of affinity tags, fusion tags, metal binding, immunoaffinity chromatography, ion exchange chromatography, size exclusion chromatography, hydrophobic interaction chromatography and HPLC. Recombinant DNA developments over the past decade have revolutionized the production of proteins in large quantities.
  • inclusion bodies that are insoluble aggregates of misfolded proteins.
  • inclusion bodies that have been the subject of many protein folding studies.
  • the conditions for refolding the denatured protein must be optimized for each specific protein, and the renaturation yield may be low even in an optimized system. Thus it is often desirable to maximize the expression of the protein in a completely soluble form.
  • US 5215895 relates to a novel cytokine that stimulates the function of cells of the immune and hematopoietic systems, and to processes for obtaining the factor and producing it by recombinant genetic engineering techniques. It describes expression of IL- l l in bacterial cells where the purification involves four ion exchange steps and cleavage of the fusion protein by hydroxylamine.
  • WO9516044A2 relates to proteins and peptide(s) fused to thioredoxin or thioredoxin-like molecules - useful for production of large amounts of heterologous proteins.
  • the fusion molecule is modified to introduce one or more metal-binding/chelating amino-acid residues to aid in purification. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell produces high levels of stable and soluble fusion protein.
  • EP 1598364A 1 discloses novel polynucleotide encoding fusion interleukin (IL)-l l receptor and IL-1 1 polypeptide.
  • US 20090036652A1 , WO 06126102A2 and US 5646016 disclose method for purification of fusion using different purification protocols.
  • US 20070141662A1 discloses a method for recombinantly producing a peptide comprising expressing the peptide as a fusion protein and applying the protease to cleave the fusion protein.
  • WO 9521 197A 1 US 20070141662A1 , EP 888384B 1 , US 7585943, and US 7442371 relates to fusion products prepared by recombinant DNA procedures.
  • the invention is related to a method for purification of recombinant human Interleukin- 1 1 from bacterial cells, the process comprising the steps of:
  • hydrophobic interaction chromatography is performed using resins selected from butyl sepharose, phenyl sepharose or octyl sepharose.
  • Ion exchange chromatography is selected from cation exchange or anion exchange or both in either order.
  • the method for purification of recombinant human Interleukin 1 1 comprises use of one or more fusion tags selected from SD tag, GM tag, T7 tag, GST tag, His tag, Trx Tag or MBP tag.
  • the SD tag used in the invention having sequence Id 1 comprises of 49 times repeated, Serine Aspartate residues.
  • the fusion tag (having a pi of 4.0) has a total of 107 amino acids.
  • Figure 1 SDS PAGE separation of Interleukin 1 1.
  • SEQ ID 1 Amino acid sequence of SD tag
  • SEQ ID 2 Nucleotide sequence of SD tag
  • SEQ ID 4 Nucleotide sequence of IL 1 1
  • IL- 1 1 is a 19 kDa polypeptide consisting of 178 amino acids, which does not contain potential glycosylation residues, disulphide bonds or other post-translational modifications and has a close similarity to IL-6. It binds to a multimeric receptor complex which contains an IL- 1 1 specific a-receptor subunit and a promiscuous ⁇ subunit (gpl 30). IL-1 1 has been demonstrated to improve platelet recovery after chemotherapy-induced thrombocytopenia, induces acute phase proteins, modulates antigen-antibody responses, participates in the regulation of bone cell proliferation and differentiation and could be use as a therapeutic for osteoporosis.
  • IL- 1 1 stimulates the growth of certain lymphocytes and, in the murine model, stimulates an increase in the cortical thickness and strength of long bones.
  • SD is an acidic protein having low pi of 4.0 present at the N terminus portion of the target protein fused (IL-1 1 ) having a pi of 1 1.16.
  • This information can be used for the purification of protein of interest from the tag by using cation exchange chromatography at pH 8.0 wherein the fusion tag, due to its low pi does not bind to the resin whereas protein of interest will bind to the cation exchange resin.
  • SD can be used as an effective tool to remove the fusion tag after cleavage by simple cation exchange chromatography.
  • This tag can be fused to any other protein of therapeutic value having a high pi point and similar strategy can be applied for their purification as well for example Interferon Beta pi, 9.69, Nesiritide pi 10.9 etc.
  • the protein obtained from the fermentation is further purified by subjecting the fusion protein to hydrophobic interaction chromatography.
  • Hydrophobic interaction chromatography is used as the first step for the purification.
  • resins which can be used for the particular application like butyl sepharose, phenyl sepharose; octyl sepharose etc.
  • the purified fusion protein may further be treated with enterokinase to cleave the fusion protein to obtain the protein of interest.
  • the above digested protein is purified by weak or strong cation exchange chromatography, preferably weak cation exchange chromatography.
  • ion exchange resins can be used such as CM sepharose, SP sepharose etc.
  • enterokinase from any sources such as bovine enterokinase, human enterokinase, porcine enterokinase or recombinant enterokinase may be used.
  • Recombinant enterokinase may be obtained from bacterial such E.coli or yeast such as Pichia pasto is may be used.
  • Enterokinase can then be removed from the IL 1 1 by the same step of cation exchange chromatography as enterokinase with pi of 5.5 will not bind to cation exchange resin and will come in the flow through along with other protein impurities.
  • target protein binds to the column which can be eluted by giving salt gradient.
  • enterokinase used in the process is recovered from the flow- through of cation exchange chromatography by loading it in an affinity chromatography resin (eg. soyabean trypsin inhibitor agarose) Sepharose resin.
  • affinity chromatography resin eg. soyabean trypsin inhibitor agarose
  • Sepharose resin eg. soyabean trypsin inhibitor agarose
  • the fusion protein may be subjected to ion exchange chromatography followed by HIC followed by enterokinase digestion and further purifying with ion exchange chromatography.
  • IL-1 1 fusion protein is active before and after cleavage with enterokinase and since it is active before cleavage also, this can be exploited to check whether the fusion protein is active or not through out the process.
  • the advantage of the present invention is that the protein of interest is having a novel fusion tag which imparts solubility to the target protein. Also the protein does not have to go through the complex process of refolding in order to have the biologically active form. In addition to it, the present invention provides a very simple and cost effective process to achieve the purity level of more than 99%.
  • fusion tag used herein refers to a fusion tag comprising Serine Aspartate residue sequence, repeated 49 times, having a total of 107 amino acids (having pi of 4.0) for separation of fusion tag from the protein of interest after cleavage using simple and cost effective purification steps.
  • the fusion tag as described provides solubility to the protein and also simplifies the purification of the target protein.
  • Hydrophobic Interaction Chromatography refers to a separation technique that uses the properties of hydrophobicity to separate proteins from one another.
  • hydrophobic groups such as phenyl, octyl, or butyl
  • proteins that pass through the column that have hydrophobic amino acid side chains on their surfaces are able to interact with and bind to the hydrophobic groups on the column.
  • a buffer with a high ionic strength, usually ammonium sulfate is initially applied to the column.
  • the salt in the buffer reduces the solvation of sample solutes thus as solvation decreases, hydrophobic regions that become exposed are adsorbed by the medium.
  • the salt concentration is gradually decreased in order of increasing hydrophobicity. Additionally, elution can also be achieved through the use of mild organic modifiers or detergent. In an embodiment the hydrophobic interaction chromatography is carried out using a salt concentration of more than 0.5 M.
  • Enterokinase is a Serine Protease enzyme which converts inactive trypsinogen into active trypsin by cleavage at the C-terminal end of the sequence. It consists of a disulfide-linked 82-140 kDa heavy chain which anchors enterokinase in the intestinal brush border membrane and a 35-62 kDa light chain which is the catalytic subunit.
  • Enterokinase cleaves after lysine at its cleavage site Asp-Asp-Asp-Asp-Lys. It will sometimes cleave at other basic residues, depending on the conformation of the protein substrate. Enterokinase will not cleave at site followed by proline.
  • Ion Exchange Chromatography relies on charge-charge interactions between the proteins and the charges immobilized on the resin.
  • Ion exchange chromatography can be subdivided into cation exchange chromatography, in which positively charged ions bind to a negatively charged resin; and anion exchange chromatography, in which the binding ions are negative, and the immobilized functional group is positive.
  • the column is washed to equilibrate it in your starting buffer, which should be of low ionic strength, then the bound molecules are eluted off using a gradient of a second buffer which steadily increases the ionic strength of the eluent solution.
  • the pH of the eluent buffer can be modified as to give the protein or the matrix a charge at which they will not interact and the molecule of interest elutes from the resin.
  • Example 1 In vitro Biological Assay
  • Cells were cultured in RPMI medium containing 10% fetal calf serum, penicillin (100 units ml "1 ), streptomycin (1 mg ml "1 ) and human IL-3 (1 ng ml “1 ) (Medium A).
  • RPMI medium containing 10% fetal calf serum, penicillin (100 units ml "1 ), streptomycin (1 mg ml “1 ) and human IL-3 (1 ng ml “1 ) (Medium A).
  • cells were pre-incubated in medium A devoid of IL-3 for 3 hours.
  • Cells (5xl 0 3 /well/100 ⁇ in Medium A devoid of IL-3) were then incubated with purified IL-1 1 (200 ng ml "1 ) in 96 well tissue culture plates for 48 hours at 37°C, 5% C0 2 .
  • MTS (20 ⁇ , Cell Titer 96 Aqueous One Solution, Promega) was added to each well and A490 was monitored after 4 hours of incubation at room temperature. A490 of control wells (without IL- 1 1 ) were subtracted from IL-1 1 treated wells to get specific absorbance of treated wells.
  • IL-1 1 obtained in this manner was seen to be 95 % active when compared with the marketed formulation.
  • Cell lysate of the fusion protein is centrifuged at 15000 rpm for 15 minutes at room temperature. Supernatant is collected and to the supernatant, NaCl is added to the final concentration of 500-2000 mM preferably 1000 mM. When NaCl is completely dissolved, Polyethylene Imine is added with constant stirring from 0.05 % to 5 % concentration, preferably 0.05% to precipitate DNA (both plasmid and host chromosomal DNA) from the cell lysate.
  • cell lysate is centrifuged at 13 to 15,000 rpm for 15 minutes between 4-25 °C. Supernatant obtained is used as starting material for purification.
  • the column is pre-equilibrated with a suitable buffer which may include 10-50 mM Tris- Cl pH 8.0, 20-50mM sodium acetate buffer, 50-100 mM sodium phosphate buffer etc.
  • a suitable buffer which may include 10-50 mM Tris- Cl pH 8.0, 20-50mM sodium acetate buffer, 50-100 mM sodium phosphate buffer etc.
  • protein should bind to the resin at a reasonably high concentration of salt. The salt concentration should be tried depending upon the hydrophobicity of the target protein i.e.1-2 M NaCl or 0.5-2 M ammonium sulphate can be used.
  • the column is washed with 5 column volumes equilibration buffer and the bound protein is eluted with 20-50 mM sodium acetate buffer, preferably 50- 100 mM sodium phosphate buffer and most preferably with 10-50 mM Tris-Cl, pH 8.0.
  • HIC eluted protein is dialyzed against 10-200 mM, preferably 20 mM Tris pH 8.0 for 16 hours in cold (4-10 °C).
  • CaCl 2 is added to the concentration of 1 - 10 mM, preferably 2-5mM.
  • Enterokinase is added for the cleavage of fusion protein in the range of 1 -5 units of Enterokinase for 400 microgram of the GMSD-IL-1 1 fusion protein at 10-30 °C, for 16 hours after which, there is almost 90 percent digestion of the fusion protein. Higher concentrations of EK could also be added for 100% fusion cleavage or by adding the same amount of EK but carrying out the EJK digestion at a higher temperature (RT-40 C).
  • Example 5 Purification using Ion Exchange Chromatography
  • the column is pre-equilibrated with sodium phosphate buffer 20-100mM, pH 7-8, 10- lOOmM Tris, pH 8.0, preferably with 20-50mM Tris, pH 8.0 .
  • the column is washed with 5 column volumes of equilibration buffer to remove loosely bound impurities.
  • the bound proteins can then be eluted with 20-100mM sodium phosphate buffer , pH 7-8, 20-50 mM Tris pH 7-8.0 containing 100-500mM NaCl.
  • CM elution is loaded onto Q sepharose at the conductivity of 20-25 mS/cm , protein of interest comes in the unbound fraction whereas the impurities are bound to the resin and is eluted in 1 M NaCl salt, the unbound protein at this step is >99% pure.
  • Reverse phase HPLC runs were carried out in Shimadzu Model 2010 CHT.
  • the analysis was done on a Vydac C4 4.6*50 50mm, 5 ⁇ column and a 2ml/min flow rate.
  • Gradient chromatography used 0.1% trifluoroacetic acid as buffer A and 0.1 % trifluroacetic acid in 90% aqueous acetonitrile as buffer B.
  • a linear gradient of 10 min from 30 to 70% B was used .
  • Samples for analysis were injected.
  • RP-HPLC Profile of in house and Innovator IL- 1 1 was performed.
  • HPLC runs used Shimadzu Model 2010 CHT.
  • the analysis used a Vydac C4 4.6*50 50mm, 5um column and a 2ml/min flow rate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de purification d'IL-11 humaine recombinante à partir de cellules microbiennes. Le procédé implique une purification faisant intervenir la chromatographie par interaction hydrophobique et la chromatographie par échange d'ions. Le procédé implique également l'utilisation d'au moins un marqueur de fusion qui confère de la solubilité à la protéine et qui simplifie également la purification de la protéine cible.
PCT/IB2011/001220 2010-06-04 2011-06-03 Procédé de purification d'il-11 humaine recombinante WO2011151716A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN608KO2010 2010-06-04
IN608/KOL/2010 2010-06-04

Publications (1)

Publication Number Publication Date
WO2011151716A1 true WO2011151716A1 (fr) 2011-12-08

Family

ID=44511714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/001220 WO2011151716A1 (fr) 2010-06-04 2011-06-03 Procédé de purification d'il-11 humaine recombinante

Country Status (1)

Country Link
WO (1) WO2011151716A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017186278A (ja) * 2016-04-07 2017-10-12 シスメックス株式会社 標的タンパク質の精製方法
CN110382524A (zh) * 2017-01-16 2019-10-25 南沙生物科技(香港)公司 用于在酵母中生产重组il-11的系统和方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215895A (en) 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
WO1995016044A2 (fr) 1993-12-10 1995-06-15 Genetics Institute, Inc. Fusions de peptides et de proteines a des molecules de thioredoxine, des molecules apparentees a la thioredoxine, et a des molecules apparentees a la thioredoxine modifiees
WO1995021197A1 (fr) 1994-02-04 1995-08-10 G.D. Searle & Co. Proteine hybride variante de l'il-3 favorisant l'hematopoiese
WO1996038570A1 (fr) * 1995-06-02 1996-12-05 Genetics Institute, Inc. Nouveaux procedes de recuperation et de purification de proteines de fusion
EP1231217A2 (fr) * 1991-02-06 2002-08-14 Genetics Institute, Inc. Fusions de peptides et de protéines à des molécules de thiorédoxine et des molécules apparentées à la thorédoxine
EP0888384B1 (fr) 1996-03-07 2002-12-11 Röwekamp, Walter Polypeptide de fusion pour influer sur les interactions entre des proteine
EP1598364A1 (fr) 2004-05-21 2005-11-23 AGIRx Limited Recepteur chimérique soluble hyper IL-11 et son utilisation
WO2006126102A2 (fr) 2005-04-20 2006-11-30 Viromed Co., Ltd. Compositions et procedes de separation de proteines hybrides
US20070141662A1 (en) 2003-11-24 2007-06-21 Novo Nordisk A/S Fusion proteins and methods of cleavage of such proteins
US7442371B2 (en) 2002-07-01 2008-10-28 Zailin Yu Recombinant human albumin-erythropoietin fusion proteins with long-lasting biological effects
US20090036652A1 (en) 2005-12-23 2009-02-05 Novo Nordisk A/S Purification of proteins using preparative reverse phase chromatography (rpc)
WO2010125588A1 (fr) * 2009-05-01 2010-11-04 Lupin Limited Nouvelle étiquette de fusion conférant un caractère soluble à une protéine recombinante insoluble

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215895A (en) 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5646016A (en) 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
EP1231217A2 (fr) * 1991-02-06 2002-08-14 Genetics Institute, Inc. Fusions de peptides et de protéines à des molécules de thiorédoxine et des molécules apparentées à la thorédoxine
WO1995016044A2 (fr) 1993-12-10 1995-06-15 Genetics Institute, Inc. Fusions de peptides et de proteines a des molecules de thioredoxine, des molecules apparentees a la thioredoxine, et a des molecules apparentees a la thioredoxine modifiees
WO1995021197A1 (fr) 1994-02-04 1995-08-10 G.D. Searle & Co. Proteine hybride variante de l'il-3 favorisant l'hematopoiese
EP1493815A1 (fr) * 1995-06-02 2005-01-05 Genetics Institute, LLC Nouveaux procédés de récupération et de purification de protéines de fusion
WO1996038570A1 (fr) * 1995-06-02 1996-12-05 Genetics Institute, Inc. Nouveaux procedes de recuperation et de purification de proteines de fusion
EP0888384B1 (fr) 1996-03-07 2002-12-11 Röwekamp, Walter Polypeptide de fusion pour influer sur les interactions entre des proteine
US7442371B2 (en) 2002-07-01 2008-10-28 Zailin Yu Recombinant human albumin-erythropoietin fusion proteins with long-lasting biological effects
US20070141662A1 (en) 2003-11-24 2007-06-21 Novo Nordisk A/S Fusion proteins and methods of cleavage of such proteins
EP1598364A1 (fr) 2004-05-21 2005-11-23 AGIRx Limited Recepteur chimérique soluble hyper IL-11 et son utilisation
WO2006126102A2 (fr) 2005-04-20 2006-11-30 Viromed Co., Ltd. Compositions et procedes de separation de proteines hybrides
US7585943B2 (en) 2005-04-20 2009-09-08 Viromed Co., Ltd. Compositions and methods for fusion protein separation
US20090036652A1 (en) 2005-12-23 2009-02-05 Novo Nordisk A/S Purification of proteins using preparative reverse phase chromatography (rpc)
WO2010125588A1 (fr) * 2009-05-01 2010-11-04 Lupin Limited Nouvelle étiquette de fusion conférant un caractère soluble à une protéine recombinante insoluble

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAVALLIE E R ET AL: "A THIOREDOXIN GENE FUSION EXPRESSION SYSTEM THAT CIRCUMVENTS INCLUSION BODY FORMATION IN THE E. COLI CYTOPLASM", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 11, no. 2, 1 February 1993 (1993-02-01), pages 187 - 193, XP000195207, ISSN: 0733-222X, DOI: 10.1038/NBT0293-187 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017186278A (ja) * 2016-04-07 2017-10-12 シスメックス株式会社 標的タンパク質の精製方法
CN107266526A (zh) * 2016-04-07 2017-10-20 希森美康株式会社 目标蛋白质的纯化方法
EP3239164A3 (fr) * 2016-04-07 2018-01-10 Sysmex Corporation Procédé de purification de protéine cible
CN107266526B (zh) * 2016-04-07 2022-05-03 希森美康株式会社 目标蛋白质的纯化方法
CN110382524A (zh) * 2017-01-16 2019-10-25 南沙生物科技(香港)公司 用于在酵母中生产重组il-11的系统和方法
JP2020505946A (ja) * 2017-01-16 2020-02-27 ナンシャ・バイオロジックス・（ホンコン）・リミテッドＮａｎｓｈａ Ｂｉｏｌｏｇｉｃｓ （Ｈｏｎｇ Ｋｏｎｇ） Ｌｉｍｉｔｅｄ 酵母における組換えｉｌ−１１の生産のためのシステムおよび方法
JP7227159B2 (ja) 2017-01-16 2023-02-21 ナンシャ・バイオロジックス・（ホンコン）・リミテッド 酵母における組換えｉｌ－１１の生産のためのシステムおよび方法
US11629367B2 (en) 2017-01-16 2023-04-18 Nansha Biologies (HK) Limited Systems and methods for production of recombinant IL-11 in yeast
CN110382524B (zh) * 2017-01-16 2024-02-06 南沙生物科技(香港)公司 用于在酵母中生产重组il-11的系统和方法

Similar Documents

Publication Publication Date Title
Swietnicki Folding aggregated proteins into functionally active forms
US11407784B2 (en) Capture purification processes for proteins expressed in a non-mammalian system
Grisshammer et al. Large-scale expression and purification of a G-protein-coupled receptor for structure determination–an overview
CN104619726A (zh) 由超折叠绿色荧光蛋白构成的融合蛋白及其用途
AU2020200572B2 (en) Novel method of protein purification
Kenig et al. Influence of the protein oligomericity on final yield after affinity tag removal in purification of recombinant proteins
US20150044718A1 (en) On-column enzymatic cleavage
TR201807352T4 (tr) Granülosit koloni stimülatör faktörünün saflaştırılmasına yönelik proses, G-CSF.
Dyr et al. Separation used for purification of recombinant proteins
US20080171857A1 (en) Process for the Purification of Recombinant Granulocyte-Colony Stimulating Factor
JP2023502335A (ja) スプリットインテインシステムを使用したタンパク質精製
US6407208B1 (en) Chimeric proteins with a cellulose binding domain
CN109055339A (zh) Tev蛋白酶突变体、基因、生物材料、制备方法、试剂或试剂盒和应用
WO2011151716A1 (fr) Procédé de purification d'il-11 humaine recombinante
Block et al. Production and comprehensive quality control of recombinant human Interleukin-1β: A case study for a process development strategy
WO2018136572A1 (fr) Construction d'expression et procédé de production de protéines d'intérêt
Jin et al. On‐column refolding of recombinant human interferon‐γ inclusion bodies by expanded bed adsorption chromatography
Su-Xia et al. Cloning and expression of a new rat procarboxypeptidase B gene in Escherichia coli and purification of recombination carboxypeptidase B
Aramvash et al. Comparison of purification processes for recombinant human growth hormone produced in E. coli
AU768443B2 (en) Method for stabilising proteins in complex mixtures during their storage in aqueous solvents
Lauritzen et al. Reliable, Large‐Scale Cleavage of Tags from Affinity‐Purified Biopharmaceuticals
Jacobson et al. Role of high-performance liquid chromatographic protein analysis in developing fermentation processes for recombinant human growth hormone, relaxin, antibody fragments and lymphotoxin
CN112210019A (zh) 一种含单跨膜区的膜蛋白其跨膜区的纯化方法
JP2002542835A (ja) アエロモナス＝アミノペプチダーゼによりポリペプチドからｎ−末端アラニン残基を除去する方法
CN116217699A (zh) 一种高效表达羊生长激素的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11729468

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2523/MUMNP/2012

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11729468

Country of ref document: EP

Kind code of ref document: A1